Healthcare AI Industry Report
Practical guidance for industry leaders as healthcare AI moves toward deployment at scale.
The 2026 Healthcare AI Industry Report translates the rapidly expanding evidence base into practical guidance for industry leaders as healthcare AI moves toward deployment at scale.
Ethan Goh, Adam Rodman, Jonathan H Chen
Supported by
Questions Industry Leaders are Asking
This report addresses and draws on on 3 questions shaping Healthcare AI deployment in 2026.
Is this technology safe, and how do we prove it?Even the best models produce harmful recommendations in 1 in 11 consultations. Capability and safety are distinct. The field has focused on the former.
Where is AI ready to deploy, and how do we get human and AI collaboration right?AI alone is outperforming physicians using AI in a growing number of studies. The missing layer of evidence is prospective trials with patient outcomes as the endpoint.
What system-level conditions can ensure healthcare AI creates real-world value?Capability is only one part of the answer. The harder challenge is institutional infrastructure: payment, regulation, privacy, and accountability.
Key Takeaways
What healthcare AI leaders should know in 2026
Chapter 1
Safety is the missing foundation
Capability is improving faster than peer review can keep up with.
Frontier models have saturated benchmarks across many clinical tasks. The bottleneck is no longer performance, but characterizing how and why these systems fail.
Safety and capability are distinct domains.
The Medical AI Superintelligence Test (MAST) shows that stronger overall performance does not translate to safer clinical behavior.
Organizations need internal evaluation capability.
No public benchmark matches a 1:1 internal use case. Institutional maturity is now defined by evaluation expertise and data pipelines.
Chapter 2
Deployment is happening. Outcomes are the next test
AI alone is outperforming physicians using AI.
Optimizing human and AI collaboration requires deliberate workflow design and real-world studies of where each falls short.
Human-in-the-loop can be flawed at scale.
Reviewing every AI-supported task creates the appearance of safety while limiting impact. The open question is which tasks can safely move toward autonomy.
The next stage of evidence is prospective.
Google's AMIE studies illustrate the shift: from simulated consultations to a real-world feasibility study at BIDMC, and now a nationwide randomized trial with Included Health.
Chapter 3
System conditions stand between capability and value
Payment models shape the AI that gets built.
Fee-for-service environments build for revenue cycle. Value-based and single-payer systems build for cost. The same technology lands differently.
If regulation does not define accountability, litigation will.
Liability does not disappear. It moves downstream to the clinicians, health systems, and vendors closest to deployment.
Infrastructure decides whether capability becomes value.
HIPAA was not designed for foundation models. Closing the gap requires named institutional ownership of AI governance.
Recommendations by stakeholder
What health systems, builders, investors, and researchers can do now
Health systems
- Designate a single institutional owner for AI evaluation and governance, reporting into the C-suite.
- Validate tools on local data; pilot in workflows with patient outcomes as the primary endpoint.
- Close the shadow AI gap with sanctioned tools and clear policies on PHI in foundation models.
Builders
- Report failure modes alongside performance; build evaluation into the product.
- Design interfaces with physician input that surface AI confidence and flag disagreements.
- Make BAAs explicit about agentic and chained workflows; compete on integration depth.
Investors
- Make evaluation infrastructure part of due diligence and post-investment monitoring.
- Prioritize prospective studies that demonstrate improved outcomes vs. standard of care.
- Stress test theses against payment-model risk and EHR-bundling risk.
Researchers
- Prioritize benchmarks that capture harm, omission, and calibration under uncertainty.
- Run prospective studies comparing AI alone, clinician alone, and AI + clinician.
- Develop accountability frameworks for AI-assisted decisions that cause harm.
How to cite
Perez, A., Tusty, M., Morgan, D., Liu, C., Wegner, L., Dutta Gupta, N., Kanjee, Z., Jain, P., Mehta, R., Walton, C., McCoy, L., Nateghi Haredasht, F., Eltahir, A. A., Griot, M., Lopez, I., Lacar, K., Schoeffler, A., Han, B., Zheng, A., Wu, D., Ravi, V., Brodeur, P., Handler, R., Manrai, A., Zwaan, L., Rodman, A., Goh, E., & Chen, J. (2026). The 2026 Healthcare AI Industry Report. ARISE, Stanford, CA.
Acknowledgements
The authors would also like to thank Abigail Foresman, David J. Wu, John Emmett Worth, Macy Toppan, Marshall Berton, Pavan Shah, Samuel O'Brien, and Zina Jawadi for their contributions.